Richard Mcgregor Email and Phone Number
Richard Mcgregor work email
- Valid
- Valid
- Valid
- Valid
Richard Mcgregor personal email
Richard Mcgregor phone numbers
Richard McGregor (richard.a.mcgregor@gmail.com) was the business lead for KBP Biosciences in the October 2023 Novo Nordisk acquisition of ocedurenone for up to $1.3 Billion (https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166329). He is recognized for his relationship-building and collaboration skills, enthusiasm and intellectual curiosity. Innovative thinker regarding adding value, and the delivery of tactical and strategic goals often under constrained financial circumstances. Experienced working with people from diverse backgrounds, institutions and functions, having the ability to progress multiple initiatives simultaneously, while performing several functions.Extensive licensing experience with 16 years in biotechnology (KBP Biosciences and Redpoint Bio), and 8 years at GlaxoSmithKline, resulting in a deep understanding of the licensing process from the perspective of both licensee and licensor. Strong science background, and understanding of the consumer, with functional expertise encompassing the fields of Business Development, Technology Licensing, Alliance Management, Medical Science Liaison, Strategic Planning, Quantitative and Qualitative Market Research, Regulatory and Scientific Affairs, Research and Development, and Intellectual Property. Proven success at identifying, developing and managing partnerships with multinational pharmaceutical, technology, food and flavor companies, and with small innovative licensees.
-
Vice President Of Business DevelopmentKbp Biosciences Mar 2024 - PresentPrinceton, Nj, Us
-
Director Of Business DevelopmentKbp Biosciences Oct 2020 - Mar 2024Princeton, Nj, UsLed Business Development for KBP Biosciences (https://www.kbpbiosciences.com/), a global, clinical stage biopharmaceutical company focused on the development of an innovative pipeline of new chemical entities with known mechanisms of action targeting underserved patient populations in organ protection and infectious diseases. KBP utilizes an integrated discovery and development platform that enables the Companyto efficiently bring new therapies from bench to patients around the world.In October 2023, Novo Nordisk acquired our lead product candidate, Ocedurenone, for up to $1.3 Billion (https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166329). Ocedurenone (https://www.kbpbio.com/index.php?c=show&id=26), is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a potentially best-in-class safety and efficacy profile. It is in Phase 3 clinical development for the treatment of uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney Disease (CKD) patients who have high risk of hyperkalemia.KBP is also developing Zifanocycline (https://www.kbpbio.com/index.php?c=show&id=25), a Phase 2 ready third-generation aminomethylcycline for the treatment of multiple strains of drug-resistant infections with high activity against certain key pathogens.KBP has built a proprietary R&D platform aimed at the discovery and development of global first-in-class compounds. The platform includes a compound library which is the basis of new compound discovery, a bacterium library aimed at multi-drug resistant bacteria, and an in vivo pharmacology platform for screening and testing new compounds. KBP Biosciences is actively seeking to identify additional promising therapeutic opportunities and further develop its product portfolio.
-
Director, Research PartnershipsJdrf International Sep 2018 - Mar 2020New York, New York, UsDriving the successful execution of JDRF’s research strategy by identifying, evaluating, and implementing external project and partnership opportunities in alignment with JDRF’s objectives.- Acting as an internal “entrepreneur” to:(i) Identify and evaluate internal and external opportunities(ii) Define and grow areas of strategic focus within JDRF’s priorities(iii) Find creative ways to advance programs through partnering(iv) Provide leadership to partnered projects -
Director, Open InnovationGlaxosmithkline Jun 2010 - Sep 2015Brentford, Middlesex, GbCore member of the Consumer Healthcare R&D Open Innovation team, and category Portfolio Management Boards. Developed, led, and executed category-specific external innovation strategies. Maintained strong relationships with a network of key vendors, collaborators, and potential partners. Primary point of contact with external innovation partners, leading due diligence of technologies. -
Associate Director, Open Innovation TeamGlaxosmithkline Nov 2007 - Oct 2011Brentford, Middlesex, GbUsed robust external search and evaluation approaches to identify breakthrough technologies. Developed and led internal program of GSK staff in various functions and locations, tasked with identifying technologies in their local regions (Global Technology Scout program). Increased awareness of GSK Open Innovation, and it’s status as partner-of-choice by presenting at industry, academic, and Open Innovation conferences.
-
Director, Technology AssessmentRedpoint Bio Corp May 1996 - Nov 2007Reporting directly to the CEO, developed new business relationships with external partners, and identified and negotiated in-licensing of technology essential to company’s growth. Alliance manager and member of steering committee for all external agreements.Scientific representative in negotiations with business and academic partners, and venture capitalists. Planned, budgeted, and wrote collaboration proposals. Led regulatory affairs program.
Richard Mcgregor Skills
Richard Mcgregor Education Details
-
University Of LeedsBiochemistry And Molecular Biology -
University Of BristolBiochemistry
Frequently Asked Questions about Richard Mcgregor
What company does Richard Mcgregor work for?
Richard Mcgregor works for Kbp Biosciences
What is Richard Mcgregor's role at the current company?
Richard Mcgregor's current role is Vice President of Business Development at KBP Biosciences.
What is Richard Mcgregor's email address?
Richard Mcgregor's email address is ri****@****gsk.com
What is Richard Mcgregor's direct phone number?
Richard Mcgregor's direct phone number is +44 20 8047*****
What schools did Richard Mcgregor attend?
Richard Mcgregor attended University Of Leeds, University Of Bristol.
What skills is Richard Mcgregor known for?
Richard Mcgregor has skills like Open Innovation, Technology Transfer, Pharmaceutical Industry, Biotechnology, Technology Evaluation, Commercialization, Drug Development, R&d, Cross Functional Team Leadership, Drug Discovery, Lifesciences, Life Sciences.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial